Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events

American Heart Journal

Volumn 157, Issue 6 SUPPL., 2009, Pages

  Papademetriou, Vasilios ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LISINOPRIL; LOSARTAN; NITRENDIPINE; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MONOTHERAPY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MYOCARDIAL ISCHEMIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 65549117366     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.04.006     Document Type: Article

References (52)

1. Centers for Disease Control and Prevention. Prevalence of Stroke-US, 2008. MMWR 56 (2007) 469-474
2. Lewington S., Clarke R., Qizilbash N., et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913 [Erratum in Lancet 2003;361:1060]
3. Psaty B.M., Smith N.L., Siscovick D.S., et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277 (1997) 739-745
4. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 278 (1997) 212-216
5. Whelton P.K., He J., Appel L.J., et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 288 (2002) 1882-1888
6. Stamler R. Implications of the INTERSALT study. Hypertension 17 1 Suppl (1991) I16-I20
7. Neaton J.D., and Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152 (1992) 56-64
8. Neaton J.D., Kuller L., Stamler J., et al. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension: pathophysiology, diagnosis and management (1995), Raven Press Publishers, New York (NY) 127-145
9. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991) 3255-3264
10. Meredith P.A., and Ostergren J. From hypertension to heart failure-are there better primary prevention strategies?. J Renin Angiotensin Aldosterone Syst 7 (2006) 64-73
11. Weber M.A., and Giles T.D. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?. Rev Cardiovasc Med 7 (2006) 45-54
12. MacMahon S. Blood Pressure Lowering Treatment Trialists' Collaboration-second cycle of analyses. Program and abstracts of the 13th European Meeting on Hypertension; June 13-17, 2003; Milan, Italy (2003)
13. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively-designed overviews of randomised trials. Arch Intern Med 165 (2005) 1410-1419
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker or diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
15. Preston R.A., Materson B.J., Reda D.J., et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 280 (1998) 1168-1172
16. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
17. Dahlof B., Sever P.S., Poulter N.R., et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
18. Farmer J.A., and Torre-Amione G. The renin angiotensin system as a risk factor for coronary artery disease. Curr Atheroscler Rep 3 (2001) 117-124
19. Hollenberg N.K., Fisher N.D., and Price D.A. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32 (1998) 387-392
20. Chrysant S.G. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens (Greenwich) 9 (2007) 454-459
21. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
22. Ibrahim M.M. RAS inhibition in hypertension. J Hum Hypertens 20 (2006) 101-108
23. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355 (2000) 1575-1581
24. Kjoller-Hansen L., Steffensen R., and Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol 35 (2000) 881-888
25. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
26. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
27. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001) 1033-1041
28. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253
29. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 (1995) 1670-1676
30. Gustafsson I., Torp-Pedersen C., Køber L., et al. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 34 (1999) 83
31. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 (1999) 376-380
32. The PEACE Trial Investigators. Angiotensin converting enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
33. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 45 (2005) 712-719
34. Kondo J., Sone T., Tsuboi H., et al. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J 146 (2003) E20
35. Yusuf S., and and the ON TARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) (Electronic publication 2008 March 3)
36. Lithell H., Hansson L., Skoog I., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-876
37. Trenkwalder P., Elmfeldt D., Hofman A., et al. The Study on COgnition and Prognosis in the Elderly (SCOPE) major CV events and stroke in subgroups of patients. Blood Press 14 (2005) 31-37
38. Schrader J., Luders S., Kulschewski A., et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34 (2003) 1699-1703 [Electronic publication ahead of print June 19, 2003]
39. Schrader J., Luders S., Kulschewski A., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
40. Staessen J., Amery A., and Fagard R. Isolated systolic hypertension in the elderly. J Hypertens 8 (1990) 393-405
41. Chobanian A.V., Bakris G.L., Black H.R., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572 [[Electronic publication ahead of print May 14, 2003]. Erratum in: JAMA 2003;290:197]
42. Franklin S.S. Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?. Curr Hyp Reports 2 (2000) 253-259
43. Papademetriou V., Farsang C., Elmfeldt D., et al. Study on COgnition and Prognosis in the Elderly study group: stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 44 (2004) 1175-1180
44. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
45. Kjeldsen S.E., Dahlof B., Devereux R.B., et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288 (2002) 1491-1498
46. Kjeldsen S.E., Lyle P.A., Kizer J.R., et al. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J Clin Hypertens (Greenwich) 7 (2005) 152-158
47. Malacco E., Vari N., Capuano V., et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 25 (2003) 2765-2780
48. Malacco E., and Palatini P. Comparison of the effects of valsartan and amlodipine alone or combined with low-dose diuretic on ambulatory blood pressure in elderly patients with isolated systolic hypertension (Val-Syst Study) [abstract]. Eur Heart J 24 (2003) 582
49. Mallion J.M., Carretta R., Trenkwalder P., et al. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl 1 (2003) 36-43
50. Oparil S., Aurup P., Snavely D., et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 87 (2001) 721-726
51. Flack J.M., Saunders E., Gradman A., et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 23 (2001) 1193-1208
52. Sacco R., Diener H.C., Yusuf S., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 (2008) 1238-1251